A new implant developed at the Technion – Israel Institute of Technology may offer a self-regulating treatment for diabetes, according to a new study in collaboration with MIT, Harvard, Johns Hopkins University, and the University of Massachusetts.
The study, led by Assistant Professor Shady Farah of the Faculty of Chemical Engineering at the Technion, was peer-reviewed and was published in Science. It introduced a “living, cell-based implant” that works as a pancreas and is protected against immune rejection by a novel system.
According to the statement, the implant “continuously senses blood-glucose levels, produces insulin within the implant itself, and releases the exact amount needed – precisely when it is needed. In effect, the implant becomes a self-regulating, drug-manufacturing organ inside the body, requiring no external pumps, injections, or patient intervention.”
Keep reading at jpost.com.
